Randomized placebo-controlled multicenter exploratory Phase IIA study to assess the safety and efficacy of PEG-liposomal prednisolone sodium phosphate (Nanocort) in subjects with active ulcerative colitis.

Trial Profile

Randomized placebo-controlled multicenter exploratory Phase IIA study to assess the safety and efficacy of PEG-liposomal prednisolone sodium phosphate (Nanocort) in subjects with active ulcerative colitis.

Completed
Phase of Trial: Phase II

Latest Information Update: 16 Mar 2016

At a glance

  • Drugs Prednisolone (Primary)
  • Indications Ulcerative colitis
  • Focus Adverse reactions
  • Sponsors Enceladus Pharmaceuticals
  • Most Recent Events

    • 16 Mar 2016 According to an Enceladus media release, results from this trial will be presented at the 11th Congress of the European Crohn's and Colitis Association (ECCO) 2016.
    • 16 Mar 2016 Results published in an Enceladus media release.
    • 22 Aug 2015 Status changed from recruiting to completed as reported by European Clinical Trials Database record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top